Advancing Novel Treatments for Hematologic Malignancies JP Morgan Conference January 2024 Exhibit 99.1

Forward-looking statements This presentation contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Syros and other matters, such as Syros’ clinical development plans, including with respect to tamibarotene, Syros’ ability to deliver benefit to patients and value to stockholders, the timing and impact of upcoming enrollment milestones and clinical data readouts, and the sufficiency of Syros’ capital resources to fund its operating expenses and capital expenditure requirements into the second quarter of 2025. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on management’s current beliefs, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation, Syros’ ability to: advance the development of its programs, including tamibarotene, under the timelines it projects in current and future clinical trials; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response seen to date with its drug candidates; successfully develop a companion diagnostic test to identify patients with the RARA biomarker; obtain and maintain patent protection for its drug candidates and the freedom to operate under third party intellectual property; obtain and maintain necessary regulatory approvals; identify, enter into out-licensing arrangements with third parties; manage competition; manage expenses; raise the substantial additional capital needed to achieve its business objectives; attract and retain qualified personnel; and successfully execute on its business strategies.  The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in Syros’ Annual Report on Form 10-K for the year ended December 31, 2022 and Syros’ Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, each of which is on file with the Securities and Exchange Commission (SEC). Except as required by applicable law, Syros undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Advancing our vision to deliver on the value of tamibarotene Commercial company delivering new standard of care for frontline treatment of hematologic malignancies Advancing tamibarotene as a potential new standard of care for HR-MDS and AML patients with RARA gene overexpression Preparing for product launch and commercialization Cash runway to fund planned operations into Q2 of 2025 Now Vision

 Advancing    Tamibarotene:  Potential to  establish new  standard   of care for the  frontline  treatment of  hematologic  malignancies   LARGE MARKET OPPORTUNITIES IN FRONTLINE SETTINGS  Building a focused infrastructure to support targeted patient populations underserved by existing options   MEANINGFUL NEAR-TERM CATALYSTS Upcoming opportunities to build momentum and create value:                pivotal SELECT-MDS-1 data and additional randomized SELECT-AML-1 data, both expected in 2024 ENCOURAGING, CONSISTENT DATA FROM MULTIPLE CLINICAL TRIALS SUPPORT DEVELOPMENT STRATEGY Growing body of evidence in MDS and AML patients with RARA overexpression     $45M FINANCING ADDS TO STRONG CORPORATE POSITION: CASH RUNWAY TO FUND OPERATIONS INTO Q2 OF 2025 

Multiple near-term value-driving milestones and pre-launch activities underway Last patient enrolled for the pivotal CR data from SELECT-MDS-1 Phase 3 trial Pivotal data from SELECT-MDS-1 Phase 3 trial       Initial data from randomized SELECT-AML-1 trial Dec. 2023 Additional data from randomized SELECT-AML-1 trial 2024 1Q 24 By mid-4Q 24 Tamibarotene in newly diagnosed HR-MDS Tamibarotene in newly diagnosed unfit AML Educating and preparing the treatment community for tamibarotene and RARA overexpression Planning distribution and sales infrastructure  Partnered with Qiagen to ensure RARA testing availability at launch  Pre-launch activities ��

Tamibarotene: Compelling profile that addresses large targeted populations Tamibarotene is a selective and potent RARa agonist1 1McKeown, Cancer Discovery 2017; 2de Botton S., et al. Blood Advances 2022 ~50% of patients with AML are positive  for RARA overexpression2 ~30%  Normal RARA overexpression with tamibarotene RARA overexpression without tamibarotene of patients with HR-MDS are positive for RARA overexpression2

Growing body of clinical evidence for tamibarotene in HR-MDS and AML patients with RARA overexpression supports development strategy 1Data presented at ASH 2017, and Syros Data on File; 2de Botton S., et al. Blood Advances 2022; 3Response includes CR, CRi or CRh; 4Data presented by Syros 06Dec2023 Single-agent tamibarotene in R/R HR-MDS patients1  Phase 2 initial randomized data evaluating Tami/Ven/Aza vs. Ven/Aza in ND unfit AML patients4 Phase 2 data evaluating Tami/Aza in  ND unfit AML patients2 Tamibarotene in HR-MDS Tami/Ven/Aza Median time to response: 21 days including one marrow CR 60% Hematologic response1 61% CR/CRi Rate 67% CR in low-blast subset Median time to response3: 1.2 months Median duration of response: 10.8 months Overall survival for complete responders: 18 months 72% Transfusion independence 2023 2017 2020 CR/CRi 70% CR/CRi TREATMENT ARM: Tami/Ven/Aza CONTROL ARM: Ven/Aza 78% CR 22% CRi 30% CR 40% CRi 100% Tamibarotene in AML

Tamibarotene has demonstrated a well-tolerated safety profile 1Amnolake® post-marketing surveillance data on file; 2Data presented at ASH 2017; 3de Botton S., et al. Blood Advances 2022; 4Data presented at ASH 2022; 5Data presented by Syros 06Dec2023 50% CRi 33% CR Data from randomized portion of SELECT-AML-1 trial Phase 2 trial expected 2023 / 2024 Single agent in AML and MDS patients and doublet (Tami/Aza) in AML patients2,3 Triplet (Tami/Ven/Aza) in AML patients4,5 Safety profile supports use of tamibarotene in combination with azacitidine in MDS and with venetoclax/azacitidine in AML Daily dosing of tamibarotene as a single-agent and in combination with azacitidine has been generally well-tolerated.2-5 No evidence of increased toxicity in combination, with rates of myelosuppression comparable to single-agent azacitidine.2-5  As a triplet, myelosuppression has been comparable to venetoclax + azacitidine4,5 The majority of non-hematologic AEs have been low grade ​and reversible2-5 Well-characterized in over 1,000 acute promyelocytic leukemia (“APL”) patients treated with tamibarotene1

Significant unmet need in newly diagnosed unfit AML 1 Ferrara F., Clin Lymphoma Myeloma Leuk. 2011; 2DiNardo CD, et al., New England Journal of Medicine, 2020; 3Maiti A., et al., Haematologica, 2021. Acute myeloid leukemia (AML) is a cancer of the blood forming cells in the bone marrow ~50% of the patients are not eligible for intensive treatment and are considered “unfit”1 Venetoclax with azacitidine is standard of care, with a 66% CR/CRi, 37% CR rate and median OS of 14.7 months2 Approximately 1/3 of patients do not respond, and nearly all relapse with a very poor prognosis, median OS of 2.4 months3 Normal AML The standard of care falls short, underscoring the critical demand for improved treatments for newly diagnosed unfit AML patients  

Randomized portion of trial ~80 patients Tamibarotene + venetoclax + azacitidine Venetoclax + azacitidine randomization (1:1) Safety lead-in completed Ongoing SELECT-AML-1 Phase 2 trial of triplet regimen (Tami/Ven/Aza) in newly diagnosed unfit AML patients with RARA overexpression Key Milestones Initial randomized SELECT-AML-1 clinical data from 23 enrolled patients^ Additional data from randomized SELECT-AML-1 trial Primary endpoint1 CR/CRi rate 2024 �� 1 The study is 80% powered to detect a difference between the CR/CRi rates in the experimental and control arms ^ Data presented by Syros 06Dec2023; Data cut-off was November 13, 2023

Initial randomized SELECT-AML-1 Phase 2 data in newly diagnosed unfit AML patients with RARA overexpression demonstrate 100% CR/CRi rate CR/CRi Rate 70% CR/CRi Rate 100% CONTROL ARM: Ven/Aza TREATMENT ARM: Tami/Ven/Aza 22% CRi 78% CR CR Rate 78% CR/CRi Rate N=9 30% CR CR/CRi Rate N=10 CR Rate 30% Data presented by Syros 06Dec2023; Data cut-off was November 13, 2023 Initial randomized data builds on previous reported data from the safety lead-in: Tamibarotene in combination with venetoclax and azacitidine was  well tolerated with no new safety signals identified 40% CRi

Initial randomized SELECT-AML-1 Phase 2 data: Hematologic safety profile shows no additive myelosuppression when combining tamibarotene with Ven/Aza Febrile neutropenia Neutropenia Thrombocytopenia Leukopenia Anemia Hematologic AEs - All Causality Tami/Ven/Aza Safety Population, N=11; Ven/Aza Safety Population, N=12* * Includes 1 patient randomized to Tami/Ven/Aza who received Ven/Aza and discontinued treatment prior to receiving tamibarotene. ^ No low-grade (Grade 1/Grade 2) Hematology AEs were reported for patients in either arm of the study. Preferred Term Regimen TEAEs reported were all Grade 3 or 4 ^ Tami/Ven/Aza Ven/Aza

1 Greenberg, Blood, 2012; 2Garcia, J et al., Leukemia Research, 2021; 3Elihu Estey, et al., Blood 2022 Higher-Risk MDS (HR-MDS) is closely related to AML Myelodysplastic syndrome (MDS) is also a cancer of the blood forming cells in the bone marrow HR-MDS often is a precursor to AML. More than half of HR-MDS patients progress to AML1 Azacitidine, a hypomethylating agent (HMA), is SOC with a 17% CR rate and a median OS of 18.6 months2 There is a significant need for new therapies - no new therapies beyond HMAs approved since 2006 “MDS-excess blasts” and “AML” essentially form a continuum…Rather than blast percentage, disease categorization may be more accurate if based on biologic features.” – Estey et al., 20223 Precursor States AML HR-MDS LR-MDS

Ongoing SELECT-MDS-1 Phase 3 trial in newly diagnosed HR-MDS patients with RARA overexpression Robustly designed, double-blind, placebo-controlled study 2:1 randomization Global study with over 120 sites recruiting in 13 countries FDA feedback supports: Focus on population with RARA overexpression CR as primary endpoint for approval (full or accelerated) with supporting data on durability of remission Azacitidine as appropriate comparator Primary endpoint of CR rate is over 90% powered to detect a difference between experimental and control arms with a one-sided alpha of 0.025 Inclusion of OS key secondary endpoint will allow this single trial to efficiently serve as a confirmatory study if needed for full approval Fast Track Designation by the FDA Key Milestones Last patient enrolled for the pivotal CR data from SELECT-MDS-1 Phase 3 trial    1Q 24 Pivotal data from SELECT-MDS-1  Phase 3 trial  SELECT-MDS-1 trial randomization (2:1) Tamibarotene + azacitidine   Placebo + azacitidine Primary endpoint CR rate (190 patients) Key secondary endpoint Overall Survival (OS) (~550 patients) by mid-4Q 24

Experienced leadership team with proven capabilities and expertise in launching targeted oncology medicines Planning our distribution and sales infrastructure strategy for a launch in the U.S. Targeted patient populations will allow for a focused, specialized sales force Partnered with Qiagen to ensure RARA testing availability Planning our commercial launch in the United States

Large market opportunities in frontline settings ~25,000 Newly Diagnosed Unfit AML patients in US and EU annually2 Building infrastructure to target synergistic patient populations underserved by existing options ~21,000 Newly Diagnosed HR-MDS patients in the US and EU annually1 ~$4.7B3 MYELODYSPLASTIC SYNDROME (MDS) ACUTE MYELOID LEUKEMIA (AML) PROJECTED MDS GLOBAL MARKET BY 2028: ~$7.5B4 PROJECTED AML  GLOBAL MARKET BY 2028: 1Epidemiology projections from DRG Myelodysplastic Syndromes-Landscape & Forecast-Report 2020 and from DRG Acute Myelogenous Leukemia-Landscape & Forecast-Report 2020;​ 2Epidemiology projections from DRG Acute Myelogenous Leukemia-Landscape & Forecast-Report 2020; 3Evaluate Pharma global market estimate includes all risk groups for MDS; 4Global market estimate includes all AML (fit and unfit)

Multiple near-term value-driving milestones and pre-launch activities underway Last patient enrolled for the pivotal CR data from SELECT-MDS-1 Phase 3 trial Pivotal data from SELECT-MDS-1 Phase 3 trial       Initial data from randomized SELECT-AML-1 trial Dec. 2023 Additional data from randomized SELECT-AML-1 trial 2024 1Q 24 by mid-4Q 24 Tamibarotene in newly diagnosed HR-MDS Tamibarotene in newly diagnosed unfit AML Educating and preparing the treatment community for tamibarotene and RARA overexpression Planning distribution and sales infrastructure  Partnered with Qiagen to ensure RARA testing availability at launch  Pre-launch activities ��